Market research
FOLD Amicus Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5B
- P/E ratio
- Not available
- Analyst target
- 14.5
- Dividend yield
- Not available
- Beta
- 0.48
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03152W1099
- Market cap
- 5B
- P/E ratio
- Not available
- Analyst target
- 14.5
- Dividend yield
- Not available
- Beta
- 0.48
About
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FOLD discussion.
5 years, 4 months ago
Amicus Therapeutics, Inc is currently in a long term downtrend where the price is trading 38.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.0.
Amicus Therapeutics, Inc's total revenue rose by 27.6% to $71M since the same quarter in the previous year.
Its net income has increased by 20.4% to $-71M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.0% to $-51M since the same quarter in the previous year.
Based on the above factors, Amicus Therapeutics, Inc gets an overall score of 4/5.